In Australia, is Addyi (Flibanserin) available or what is available?
Australia Leads the Way in Androgen Treatment for Women with HSDD
While the US-approved drug flibanserin offers limited benefit for Hypoactive Sexual Desire Disorder (HSDD), it’s not approved in Australia—and comes with notable side effects.
Instead, Australia is the only country in the world to approve a regulated androgen hormone treatment specifically for postmenopausal women with HSDD. This topical therapy restores androgen levels to those typical of premenopausal women and is backed by decades of Australian-led research.
This marks a major step forward in addressing gender equity in sexual health care.
Latest News
Free CPD Education: Diagnose & Manage HSDD
Empower Your Practice: Address HSDD with Confidence Hypoactive Sexual Desire Disorder (HSDD) is a common yet often overlooked concern in general practice—especially among postmenopausal… Continue Reading →
Supporting Sexual Function—Understanding the Different Challenges Women May Face
Understanding Sexual Function and Common Challenges in Women Sexual dysfunction affects up to 43% of women, and it’s more than just low desire. There are… Continue Reading →
Impact of Menopause on Sexual Health—What You Might Not Know
Menopause and Sexual Health—What You Might Not Know The menopause transition can bring unexpected changes to your sex life. Fluctuating hormones, vaginal dryness, and… Continue Reading →